3. Spinal muscular atrophy Clinical trials / Disease details
Clinical trials : 217 / Drugs : 149 - (DrugBank : 33) / Drug target genes : 54 - Drug target pathways : 80
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02876094 (ClinicalTrials.gov) | January 29, 2019 | 9/8/2016 | Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy | A Pilot, Open-Label, Dose Response Study Investigating the Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy (SMA) | Drug: celecoxib | Hugh McMillan | Families of Spinal Muscular Atrophy;Gwendolyn Strong Foundation | Terminated | 2 Years | 80 Years | All | 1 | Phase 2 | Canada |